Makro-Albumon (Human Albumin As Macroaggregates)

Human Albumin increases the oncotic pressure of plasma, drawing water from the interstitial space into the vascular compartment. This expands circulating blood volume, enhances cardiac preload, and supports tissue perfusion without directly affecting vascular tone or heart contractility.

The dose of Makro-Albumon is individualized and determined by the prescribing clinician based on the patient’s clinical condition, severity of volume loss, and laboratory parameters. No fixed regimen is provided; dosing is adjusted to achieve the desired plasma volume expansion.

Safety data for Makro-Albumon in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Makro-Albumon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Makro-Albumon provides oncotic pressure similar to native human albumin, offering a physiological volume expansion compared with synthetic colloids or crystalloids. It is less likely to cause coagulopathy than some synthetic agents and is preferred when albumin replacement is specifically indicated, such as in hypoalbuminemia.

Makro-Albumon must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use if the product appears discolored or contains particles.

Makro-Albumon is administered intravenously, typically as an infusion. The rate and volume are determined by the prescriber, taking into account the patient’s fluid status and clinical response. Infusion should be performed under medical supervision with monitoring for adverse reactions.

Serious risks include anaphylactic reactions, volume overload leading to pulmonary edema, thromboembolic events, hemolysis, and acute renal failure. Patients should be closely monitored for signs of these events, especially during and after infusion.

Makro-Albumon is contraindicated in patients with known hypersensitivity to human albumin or any component of the formulation, and in those with uncontrolled fluid overload or severe heart failure where additional volume expansion could be harmful.